PT2306977E - Método e composição para tratamento de hipertensão ocular e glaucoma - Google Patents

Método e composição para tratamento de hipertensão ocular e glaucoma Download PDF

Info

Publication number: PT2306977E
Authority: PT; Portugal
Prior art keywords: glaucoma; composition; ocular hypertension; treating ocular; treating
Prior art date: 2008-05-30

Application number

PT97548648T

Other languages

English (en)

Inventor

Olli Oksala

Timo Reunamaki

Pertti Pellinen

Kari Lehmussaari

Original Assignee

Santen Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-30

Filing date

2009-05-28

Publication date

2014-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2306977(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-28 Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd

2014-09-22 Publication of PT2306977E publication Critical patent/PT2306977E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT97548648T 2008-05-30 2009-05-28 Método e composição para tratamento de hipertensão ocular e glaucoma PT2306977E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP08397513A EP2127638A1 (en)	2008-05-30	2008-05-30	Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number	Publication Date
PT2306977E true PT2306977E (pt)	2014-09-22

Family

ID=39940592

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT201646023T PT3714877T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma
PT170004402T PT3205334T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma
PT97548648T PT2306977E (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma
PT140018623T PT2772249T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT201646023T PT3714877T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma
PT170004402T PT3205334T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT140018623T PT2772249T (pt)	2008-05-30	2009-05-28	Método e composição para tratamento de hipertensão ocular e glaucoma

Country Status (27)

Country	Link
US (3)	US9999593B2 (pt)
EP (7)	EP2127638A1 (pt)
JP (9)	JP2011521943A (pt)
KR (5)	KR102246598B1 (pt)
CN (1)	CN102083413B (pt)
AR (2)	AR071937A1 (pt)
AU (1)	AU2009252210C1 (pt)
BR (1)	BRPI0913109B8 (pt)
CA (2)	CA2724194C (pt)
CY (2)	CY1115565T1 (pt)
DK (4)	DK2306977T3 (pt)
EA (1)	EA023661B1 (pt)
ES (5)	ES2907982T3 (pt)
GE (1)	GEP20156220B (pt)
HR (4)	HRP20220361T1 (pt)
HU (3)	HUE033103T2 (pt)
JO (1)	JO3039B1 (pt)
LT (3)	LT3205334T (pt)
MX (1)	MX2010012987A (pt)
MY (1)	MY159463A (pt)
PL (4)	PL2772249T3 (pt)
PT (4)	PT3714877T (pt)
SG (1)	SG191628A1 (pt)
SI (4)	SI2772249T1 (pt)
TW (1)	TWI432202B (pt)
UA (1)	UA102257C2 (pt)
WO (1)	WO2009145356A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI544927B (zh)	2008-03-17	2016-08-11	愛爾康研究有限公司	具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) *	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en)	2009-03-04	2010-09-15	Novagali Pharma S.A.	Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en)	2010-05-28	2011-11-30	Novagali Pharma S.A.	Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) *	2009-12-09	2011-06-09	Burk Robert M	Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) *	2009-12-28	2015-03-11	ロート製薬株式会社	眼科用組成物
FR2961694B1 (fr) *	2010-06-29	2013-01-25	Thea Lab	Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) *	2010-07-29	2015-06-23	Allergan, Inc.	Preservative free bimatoprost and timolol solutions
EP2598118B1 (en) *	2010-07-29	2018-09-05	Allergan, Inc.	Preservative free bimatoprost and timolol solutions
US20130245124A1 (en) *	2010-07-29	2013-09-19	Allergan, Inc.	Preservative free bimatoprost solutions
WO2012021107A2 (en)	2010-08-12	2012-02-16	Nanyang Technological University	A liposomal formulation for ocular drug delivery
EP2618810B1 (en)	2010-09-21	2016-11-23	S & V Technologies GmbH	Cosmetic composition
EP2452669A1 (en) *	2010-10-29	2012-05-16	Omnivision GmbH	Ophthalmic composition
KR20140038404A (ko) *	2011-04-12	2014-03-28	가부시키가이샤 아루떼꾸 우에노	수성 안과용 조성물
CN102716074B (zh) *	2012-06-28	2013-10-16	武汉武药科技有限公司	一种贝美前列素滴眼剂及其制备方法
CA2914472C (en) *	2012-08-24	2019-09-03	Ashim K. Mitra	Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en)	2014-01-07	2018-05-01	Nanyang Technological University	Stable liposomal formulations for ocular drug delivery
JP2017502089A (ja)	2014-01-10	2017-01-19	マニスティーパートナーズエルエルシーＭａｎｉｓｔｅｅＰａｒｔｎｅｒｓＬｌｃ	偏頭痛の処置
CN104766952B (zh) *	2015-04-21	2017-01-25	武汉凯迪工程技术研究总院有限公司	利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es)	2015-06-09	2020-03-10	Medproject Pharma Entw Und Vertriebsgesellschaft Mbh	Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) *	2015-10-09	2018-10-23	Tamara Vrabec	Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
US20180325854A1 (en) *	2015-11-06	2018-11-15	Accuitis Pharmaceuticals, Inc.	Use of proteasome inhibitors to treat ocular disorders
EP3373976B1 (en)	2015-11-10	2024-01-03	Sun Pharmaceutical Industries Limited	Topical formulations and uses thereof
JP7072517B2 (ja)	2016-02-29	2022-05-20	サンファーマグローバルエフゼットイー	局所用シクロスポリン含有製剤およびその使用
GR1009040B (el) *	2016-04-19	2017-05-19	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) *	2016-08-15	2018-02-22	Santen Pharmaceutical Co., Ltd.	Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) *	2016-11-09	2017-08-22	주식회사태준제약	안압 강하용 점안 조성물
JP2020059652A (ja) *	2016-12-26	2020-04-16	参天製薬株式会社	タフルプロストとクエン酸エステルとを含有するデポ剤
WO2018181294A1 (ja) *	2017-03-27	2018-10-04	興和株式会社	医薬製剤
US20180318319A1 (en) *	2017-05-04	2018-11-08	Ocular Science, Inc.	Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en)	2017-06-22	2021-03-17	Yonsung Fine Chemical Co., Ltd.	OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
TWI833535B (zh) *	2017-12-21	2024-02-21	日商參天製藥股份有限公司	賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
US20210282965A1 (en)	2018-07-09	2021-09-16	Warszawskie Zaklady Farmaceutyczne Polfa Sa	Opthalmic dispensing device
CN111632025A (zh) *	2020-03-04	2020-09-08	吉林大学第一医院	一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) *	2020-08-12	2021-09-14	陈丽娜	一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) *	2021-02-11	2021-12-13	Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс")	Фармацевтическая композиция тафлупроста
TW202400133A (zh) *	2022-03-25	2024-01-01	日商坪田實驗室股份有限公司	水性組成物
WO2023241652A1 (zh) *	2022-06-16	2023-12-21	广州润尔眼科生物科技有限公司	一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) *	2023-03-24	2024-10-03	株式会社坪田ラボ	水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4778815A (en) *	1987-03-18	1988-10-18	Ciba-Geigy Corporation	Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
ATE76750T1 (de)	1987-04-03	1992-06-15	Univ Columbia	Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
US5409125A (en)	1989-12-11	1995-04-25	Aktiebolaget Astra	Unit dose container
DE4027320C2 (de)	1990-08-29	1993-09-30	Ursapharm Arzneimittel Gmbh	Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja)	1992-08-04	1994-03-01	Aavan Internatl:Kk	洗面台カウンター及びその製造方法
JPH06107547A (ja)	1992-10-01	1994-04-19	Aarutetsuku Ueno:Kk	眼科用組成物
AU665287B2 (en)	1992-12-21	1995-12-21	Alcon Laboratories, Inc.	Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja)	1993-01-20	1996-09-11	東洋製罐株式会社	加熱殺菌可能な液体医薬容器
US5807892A (en)	1994-09-30	1998-09-15	Alcon Laboratories, Inc.	Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en)	1994-12-22	1997-05-20	Alcon Laboratories, Inc.	Storage-stable prostaglandin compositions
WO1997018812A1 (en) *	1995-11-17	1997-05-29	Alcon Laboratories, Inc.	Combination therapy for treating glaucoma
DE69714274T3 (de)	1996-09-17	2006-06-01	Asahi Glass Co., Ltd.	Fluorierte prostaglandinderivate und medikamente
EP0944530A1 (en)	1996-12-09	1999-09-29	Bausch & Lomb Incorporated	Single-use flexible container
JP3480549B2 (ja)	1996-12-26	2003-12-22	参天製薬株式会社	ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es)	1997-03-17	1998-01-07	Sanchez Reynaldo Alemany	Instrumento computarizado para el analisis del movimiento.
CA2274708A1 (en) *	1997-10-13	1999-04-22	R-Tech Ueno, Ltd.	Remedial composition for intraocular hypertension or glaucoma
US6066671A (en)	1997-12-19	2000-05-23	Alcon Laboratories, Inc.	Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en)	1998-05-26	2000-11-15	Spreckelsen Mcgeough Ltd	Fluid packaging
US6235781B1 (en)	1998-07-14	2001-05-22	Alcon Laboratories, Inc.	Prostaglandin product
EP1011728B1 (en) *	1998-07-14	2004-12-29	Alcon Manufacturing, Ltd.	Polypropylene containers for prostaglandin products
JP2003517441A (ja)	1998-09-25	2003-05-27	アルコンラボラトリーズ，インコーポレイテッド	徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en)	1998-12-15	2000-08-01	Alcon Laboratories, Inc.	Cyclobutane prostaglandin analogues as ocular hypotensive agents
WO2000038663A2 (en)	1998-12-24	2000-07-06	Alcon Laboratories, Inc.	Ep4 receptor agonists for treatment of dry eye
PT1466889E (pt)	1999-04-06	2008-07-02	Sepracor Inc	Succinato de o-desmetilvenlafaxina
AU2001264261A1 (en)	2000-06-19	2002-01-02	Santen Pharmaceutical Co. Ltd.	Aseptics
JP3876355B2 (ja) *	2000-09-13	2007-01-31	参天製薬株式会社	点眼液
ES2357551T3 (es)	2000-09-13	2011-04-27	Santen Pharmaceutical Co., Ltd.	Colirio.
TW586946B (en)	2000-12-22	2004-05-11	Novartis Ag	Process to improve stability
WO2004006826A1 (ja)	2002-07-16	2004-01-22	Senju Pharmaceutical Co., Ltd.	薬液容器及びその製造方法
KR101182496B1 (ko)	2002-09-09	2012-09-12	산텐 세이야꾸 가부시키가이샤	라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) *	2002-10-24	2006-07-11	Sucampo Ag (Usa) Inc.	Method for treating ocular hypertension and glaucoma
WO2005011704A1 (ja) *	2003-07-31	2005-02-10	Santen Pharmaceutical Co., Ltd.	プロスタグランジン含有製品
US20050287325A1 (en)	2004-06-25	2005-12-29	Pharmacia & Upjohn Company	Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ATE412400T1 (de) *	2004-11-09	2008-11-15	Novagali Pharma Sa	Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
WO2006058139A2 (en)	2004-11-24	2006-06-01	Holopack International Corp.	Dispensing container with flow control system
CA2590277C (en)	2004-12-09	2014-07-08	Santen Pharmaceutical Co., Ltd.	Product containing prostaglandin having fluorine atom in its molecule
ATE555792T1 (de)	2004-12-24	2012-05-15	Santen Pharmaceutical Co Ltd	Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) *	2005-01-20	2005-03-02	Resolution Chemicals Ltd	Stable prostaglandin-containing compositions
RU2413534C2 (ru) *	2005-07-13	2011-03-10	Сантен Фармасьютикал Ко., Лтд.	Консервирующая композиция для офтальмологического применения
EP1916002B1 (en)	2005-08-02	2014-03-05	Santen Pharmaceutical Co., Ltd.	Method for prevention of degradation of thermally unstable substance
DK1937212T3 (da)	2005-10-10	2010-12-13	Novagali Pharma Sa	Oftalmiske emulsioner indeholdende prostaglandiner
FI126233B (sv)	2006-02-23	2016-08-31	Oy Kwh Mirka Ab	Oscillerande slipmaskin
FR2918891B1 (fr)	2007-07-20	2009-09-25	Thea Sa Lab	Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko)	2007-11-26	2009-11-23	한국표준과학연구원	열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en)	2008-05-30	2009-12-02	Santen Pharmaceutical Co., Ltd	Method and composition for treating ocular hypertension and glaucoma

2008
- 2008-05-30 EP EP08397513A patent/EP2127638A1/en not_active Withdrawn
2009
- 2009-05-19 TW TW098116503A patent/TWI432202B/zh active
- 2009-05-27 JO JOP/2009/0192A patent/JO3039B1/ar active
- 2009-05-28 EP EP21217057.5A patent/EP4035656B1/en active Active
- 2009-05-28 BR BRPI0913109A patent/BRPI0913109B8/pt active IP Right Grant
- 2009-05-28 MY MYPI2010005463A patent/MY159463A/en unknown
- 2009-05-28 LT LTEP17000440.2T patent/LT3205334T/lt unknown
- 2009-05-28 KR KR1020207014211A patent/KR102246598B1/ko active IP Right Grant
- 2009-05-28 HU HUE14001862A patent/HUE033103T2/en unknown
- 2009-05-28 DK DK09754864.8T patent/DK2306977T3/da active
- 2009-05-28 EP EP20164602.3A patent/EP3714877B1/en active Active
- 2009-05-28 PT PT201646023T patent/PT3714877T/pt unknown
- 2009-05-28 UA UAA201015619A patent/UA102257C2/uk unknown
- 2009-05-28 WO PCT/JP2009/060211 patent/WO2009145356A1/en active Application Filing
- 2009-05-28 DK DK14001862.3T patent/DK2772249T3/en active
- 2009-05-28 PL PL14001862T patent/PL2772249T3/pl unknown
- 2009-05-28 ES ES20164602T patent/ES2907982T3/es active Active
- 2009-05-28 EA EA201071413A patent/EA023661B1/ru unknown
- 2009-05-28 EP EP23202597.3A patent/EP4289446A3/en active Pending
- 2009-05-28 ES ES17000440T patent/ES2808050T3/es active Active
- 2009-05-28 SI SI200931694T patent/SI2772249T1/sl unknown
- 2009-05-28 CA CA2724194A patent/CA2724194C/en active Active
- 2009-05-28 KR KR1020107029072A patent/KR101650006B1/ko active IP Right Grant
- 2009-05-28 HR HRP20220361TT patent/HRP20220361T1/hr unknown
- 2009-05-28 SG SG2013041751A patent/SG191628A1/en unknown
- 2009-05-28 KR KR1020187001130A patent/KR101988642B1/ko active IP Right Grant
- 2009-05-28 CN CN2009801197245A patent/CN102083413B/zh active Active
- 2009-05-28 AR ARP090101912A patent/AR071937A1/es not_active Application Discontinuation
- 2009-05-28 PT PT170004402T patent/PT3205334T/pt unknown
- 2009-05-28 US US12/995,351 patent/US9999593B2/en active Active
- 2009-05-28 ES ES09754864.8T patent/ES2495316T3/es active Active
- 2009-05-28 PL PL09754864T patent/PL2306977T3/pl unknown
- 2009-05-28 PT PT97548648T patent/PT2306977E/pt unknown
- 2009-05-28 LT LTEP20164602.3T patent/LT3714877T/lt unknown
- 2009-05-28 HU HUE20164602A patent/HUE058079T2/hu unknown
- 2009-05-28 GE GEAP200912045A patent/GEP20156220B/en unknown
- 2009-05-28 SI SI200931050T patent/SI2306977T1/sl unknown
- 2009-05-28 PT PT140018623T patent/PT2772249T/pt unknown
- 2009-05-28 PL PL17000440T patent/PL3205334T3/pl unknown
- 2009-05-28 EP EP17000440.2A patent/EP3205334B1/en active Active
- 2009-05-28 DK DK20164602.3T patent/DK3714877T3/da active
- 2009-05-28 CA CA2965185A patent/CA2965185A1/en not_active Abandoned
- 2009-05-28 KR KR1020167022210A patent/KR101820816B1/ko active IP Right Grant
- 2009-05-28 AU AU2009252210A patent/AU2009252210C1/en active Active
- 2009-05-28 SI SI200932073T patent/SI3205334T1/sl unknown
- 2009-05-28 JP JP2011511256A patent/JP2011521943A/ja active Pending
- 2009-05-28 MX MX2010012987A patent/MX2010012987A/es active IP Right Grant
- 2009-05-28 PL PL20164602T patent/PL3714877T3/pl unknown
- 2009-05-28 EP EP14001862.3A patent/EP2772249B1/en not_active Revoked
- 2009-05-28 EP EP09754864.8A patent/EP2306977B1/en active Active
- 2009-05-28 HU HUE17000440A patent/HUE049923T2/hu unknown
- 2009-05-28 KR KR1020197016340A patent/KR102114401B1/ko active IP Right Grant
- 2009-05-28 SI SI200932159T patent/SI3714877T1/sl unknown
- 2009-05-28 DK DK17000440.2T patent/DK3205334T3/da active
- 2009-05-28 ES ES14001862.3T patent/ES2627837T3/es active Active
- 2009-05-28 LT LTEP14001862.3T patent/LT2772249T/lt unknown
- 2009-05-28 ES ES21217057T patent/ES2968837T3/es active Active
2014
- 2014-04-22 JP JP2014088256A patent/JP2014133765A/ja active Pending
- 2014-09-18 CY CY20141100763T patent/CY1115565T1/el unknown
- 2014-10-14 HR HRP20140979AT patent/HRP20140979T1/hr unknown
2015
- 2015-12-07 JP JP2015238594A patent/JP6148317B2/ja active Active
2017
- 2017-05-18 JP JP2017098843A patent/JP6356868B2/ja active Active
- 2017-05-23 HR HRP20170769TT patent/HRP20170769T1/hr unknown
- 2017-06-27 CY CY20171100675T patent/CY1120351T1/el unknown
2018
- 2018-06-14 JP JP2018113647A patent/JP6649992B2/ja active Active
- 2018-06-18 US US16/010,739 patent/US10864159B2/en active Active
- 2018-11-01 AR ARP180103181A patent/AR120961A2/es not_active Application Discontinuation
2020
- 2020-01-17 JP JP2020005799A patent/JP6889789B2/ja active Active
- 2020-06-24 HR HRP20200998TT patent/HRP20200998T1/hr unknown
- 2020-11-11 US US17/094,986 patent/US20210059931A1/en not_active Abandoned
2021
- 2021-05-21 JP JP2021085839A patent/JP7265584B2/ja active Active
2023
- 2023-04-14 JP JP2023066348A patent/JP7520285B2/ja active Active
2024
- 2024-04-12 JP JP2024064531A patent/JP2024079852A/ja active Pending

Also Published As

Publication number	Publication date
EP4035656B1 (en)	2023-11-22
KR101988642B1 (ko)	2019-06-12
PL2306977T3 (pl)	2015-01-30
AR071937A1 (es)	2010-07-28
EP4289446A3 (en)	2024-01-10
KR101820816B1 (ko)	2018-01-22
ES2968837T3 (es)	2024-05-14
DK2306977T3 (da)	2014-09-15
KR20110011707A (ko)	2011-02-08
ES2627837T8 (es)	2018-02-26
JP2020073574A (ja)	2020-05-14
SI3714877T1 (sl)	2022-05-31
ES2907982T3 (es)	2022-04-27
JP7265584B2 (ja)	2023-04-26
CA2724194C (en)	2017-06-27
ES2495316T3 (es)	2014-09-17
PT3205334T (pt)	2020-07-31
KR102246598B1 (ko)	2021-04-30
EP4035656A1 (en)	2022-08-03
KR20200057801A (ko)	2020-05-26
JP6649992B2 (ja)	2020-02-19
PT3714877T (pt)	2022-03-10
EP3714877B1 (en)	2022-01-26
CY1120351T1 (el)	2019-07-10
EA023661B1 (ru)	2016-06-30
JP2017178957A (ja)	2017-10-05
CN102083413B (zh)	2013-11-06
JP6889789B2 (ja)	2021-06-18
LT2772249T (lt)	2017-09-11
KR102114401B1 (ko)	2020-05-25
GEP20156220B (en)	2015-01-26
AU2009252210A1 (en)	2009-12-03
AR120961A2 (es)	2022-04-06
KR20190067272A (ko)	2019-06-14
HUE058079T2 (hu)	2022-06-28
JP2024079852A (ja)	2024-06-11
PL3205334T3 (pl)	2020-11-02
MX2010012987A (es)	2011-02-24
EP2306977B1 (en)	2014-08-13
HRP20200998T1 (hr)	2020-10-16
SI2772249T1 (sl)	2017-08-31
PL3714877T3 (pl)	2022-05-16
HRP20140979T1 (hr)	2014-11-21
EP2772249A1 (en)	2014-09-03
JP6148317B2 (ja)	2017-06-14
DK2772249T3 (en)	2017-07-17
JP2021120412A (ja)	2021-08-19
KR20180008905A (ko)	2018-01-24
JP2014133765A (ja)	2014-07-24
SG191628A1 (en)	2013-07-31
JO3039B1 (ar)	2016-09-05
CY1115565T1 (el)	2017-01-04
EP3205334B1 (en)	2020-04-29
EP3205334A1 (en)	2017-08-16
DK3714877T3 (da)	2022-02-14
PT2772249T (pt)	2017-08-08
AU2009252210C1 (en)	2016-04-14
HRP20170769T1 (hr)	2017-08-11
DK3205334T3 (da)	2020-07-13
EP2772249B1 (en)	2017-05-03
US10864159B2 (en)	2020-12-15
JP2016065095A (ja)	2016-04-28
CN102083413A (zh)	2011-06-01
LT3714877T (lt)	2022-04-11
WO2009145356A1 (en)	2009-12-03
JP2011521943A (ja)	2011-07-28
HUE033103T2 (en)	2017-11-28
AU2009252210B2 (en)	2014-10-16
BRPI0913109A2 (pt)	2017-06-20
ES2808050T3 (es)	2021-02-25
PL2772249T3 (pl)	2017-10-31
EP3714877A1 (en)	2020-09-30
JP7520285B2 (ja)	2024-07-23
BRPI0913109B8 (pt)	2021-05-25
ES2627837T3 (es)	2017-07-31
SI2306977T1 (sl)	2014-12-31
SI3205334T1 (sl)	2020-10-30
HUE049923T2 (hu)	2020-11-30
KR20160102319A (ko)	2016-08-29
TWI432202B (zh)	2014-04-01
UA102257C2 (uk)	2013-06-25
US20210059931A1 (en)	2021-03-04
TW201000104A (en)	2010-01-01
US20110152264A1 (en)	2011-06-23
JP6356868B2 (ja)	2018-07-11
EA201071413A1 (ru)	2011-06-30
EP4289446A2 (en)	2023-12-13
MY159463A (en)	2017-01-13
BRPI0913109B1 (pt)	2019-10-22
EP2306977A1 (en)	2011-04-13
US20180289618A1 (en)	2018-10-11
CA2965185A1 (en)	2009-12-03
LT3205334T (lt)	2020-09-25
EP2127638A1 (en)	2009-12-02
CA2724194A1 (en)	2009-12-03
KR101650006B1 (ko)	2016-08-22
US9999593B2 (en)	2018-06-19
JP2023085558A (ja)	2023-06-20
HRP20220361T1 (hr)	2022-05-13
JP2018154656A (ja)	2018-10-04

Publication	Publication Date	Title
PT2772249T (pt)	2017-08-08	Método e composição para tratamento de hipertensão ocular e glaucoma
HK1247821A1 (zh)	2018-10-05	用於預防或治療眼科病症的方法和組合物
EP2083862A4 (en)	2012-09-19	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
IL186598A0 (en)	2008-11-03	Composition and method for the treatment or prevention of glaucoma and ocular hypertension
PT2374472T (pt)	2018-08-08	Composições e métodos para o tratamento de afeções oftalmológicas
IL202015A0 (en)	2010-06-16	Methods and compositions for treating skin conditions
IL209948A0 (en)	2011-02-28	Method of eye treatment for prevention of presbyopia and glaucoma, and means for carrying out said treatment
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
IL207397A0 (en)	2010-12-30	Difluorobiphenylamide derivtives for the treatment of ocular hypertension
HK1149545A1 (en)	2011-10-07	Compositions and methods for treating ophthalmic diseases
EP2120994A4 (en)	2011-09-28	METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
GB0718918D0 (en)	2007-11-07	Compositions and methods for treating skin conditions
EP2032130A4 (en)	2011-03-02	OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF EYE HIGH PRESSURE
IL209947A0 (en)	2011-02-28	Compositions and methods for treating corneal inflammation
EP2427052A4 (en)	2012-09-05	METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS
AU2013207600A1 (en)	2013-08-08	Methods and apparatus for treating glaucoma
IL197323A0 (en)	2009-12-24	Novel method and compositions for prevention or treatment of glaucoma and ocular hypertension